- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02308501
A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Have a positive history of ocular allergies and a positive skin test to protocol defined allergens
- Have a positive CAC reaction at Visit 1
- Have a positive conjunctival inflammation score at Visit 1
Exclusion Criteria:
- May not use disallowed medications in specified washout period
- May not have an ocular or system disease the investigator feels with impact subject safety or trial parameters
- May not have active ocular infection
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Lastacaft ®
One drop Lastacaft ® in right eye or left eye based on randomization list once on Day 1 and once on Day 2
|
|
|
Placebo komparator: Tears Naturale ®
One drop Tears Naturale ® in right eye or left eye based on randomization list once on Day 1 and once on Day 2
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Conjunctival Inflammation at 1 Hour (+30 Minutes) Post CAC on Day 1
Tidsramme: 1 hour (+30 minutes) post CAC on Day 1
|
Conjunctival Inflammation was assessed by a trained technician post-conjunctival allergen challenge (CAC) on a 0 to 4 scale (0 = best [least inflammation] and 4 = worst [most inflammation]). The Conjunctival Inflammation was averaged across all Lastacaft-treated eyes to create the average Lastacaft eye Conjunctival Inflammation score, and the Conjunctival Inflammation score was averaged across all Tears Naturale-treated eyes to create the average Tears Naturale eye Conjunctival Inflammation score. |
1 hour (+30 minutes) post CAC on Day 1
|
|
Conjunctival Inflammation 1 Hour (+30 Minutes) Post CAC on Day 2
Tidsramme: 1 hour (+30 minutes) post CAC on Day 2
|
Conjunctival Inflammation was assessed by a trained technician post-conjunctival allergen challenge (CAC) on a 0 to 4 scale (0 = best [least inflammation] and 4 = worst [most inflammation]). The Conjunctival Inflammation was averaged across all Lastacaft-treated eyes to create the average Lastacaft eye Conjunctival Inflammation score, and the Conjunctival Inflammation score was averaged across all Tears Naturale-treated eyes to create the average Tears Naturale eye Conjunctival Inflammation score. |
1 hour (+30 minutes) post CAC on Day 2
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Ocular Itching on Day 1 (15 Minutes Post-study Medication Instillation)
Tidsramme: 15 minutes post-study medication instillation
|
CAC was performed 15 minutes after study medication instillation.
Ocular Itching was assessed by the patient on a 0-4 scale (0 = best [no itching] to 4 = worst [severe itching]).
The ocular itching score was averaged across all Lastacaft-treated eyes to create the average Lastacaft eye ocular itching score, and the ocular itching score was averaged across all Tears Naturale-treated eyes to create the average Tears Naturale eye ocular itching score.
|
15 minutes post-study medication instillation
|
|
Ocular Itching on Day 2 (15 Minutes Post-study Medication Instillation)
Tidsramme: 15 minutes post-study medication instillation
|
CAC was performed 15 minutes after study medication instillation.
Ocular Itching was assessed by the patient on a 0-4 scale (0 = best [no itching] to 4 = worst [severe itching]).
The ocular itching score was averaged across all Lastacaft-treated eyes to create the average Lastacaft eye ocular itching score, and the ocular itching score was averaged across all Tears Naturale-treated eyes to create the average Tears Naturale eye ocular itching score.
|
15 minutes post-study medication instillation
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i immunsystemet
- Overfølsomhed, Øjeblikkelig
- Øjensygdomme
- Overfølsomhed
- Konjunktivale sygdomme
- Konjunktivitis
- Konjunktivitis, Allergisk
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Histamin H1-antagonister
- Histaminantagonister
- Histaminmidler
- Alcaftadin
Andre undersøgelses-id-numre
- 14-100-0012
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Allergisk konjunktivitis
-
AnergisInflamax Research IncorporatedAfsluttetAllergisk Rhino-ConjunctivitisCanada
-
Humanis Saglık Anonim SirketiAfsluttet
-
Harrow IncEyevance PharmaceuticalsAfsluttetPostoperative komplikationer | Øjenbetændelse | Syndromer med tørre øjne | Keratokonjunktivitis | Tørre øjne (DED) | Postoperative komplikationer | Kerato Conjunctivitis SiccaForenede Stater
-
C.O.C. Farmaceutici S.r.l.AfsluttetTørre øjne | Tør øjensygdom | Kerato Conjunctivitis SiccaItalien
-
Kala Pharmaceuticals, Inc.AfsluttetKerato Conjunctivitis SiccaForenede Stater
-
Oyster Point Pharma, Inc.AfsluttetTørre øjne | Kerato Conjunctivitis SiccaForenede Stater
-
Glaukos CorporationAfsluttetSikkerhed og effektivitet af Pilocarpin Ophthalmic Topical Cream til behandling af tørre øjne sygdomTør øjensygdom | Kerato Conjunctivitis SiccaForenede Stater
-
Mimetogen Pharmaceuticals USA, Inc.AfsluttetSyndromer med tørre øjne | Tør øjensygdom | Kerato Conjunctivitis SiccaForenede Stater
-
C.O.C. Farmaceutici S.r.l.AfsluttetTørre øjne | Tør øjensygdom | Kerato Conjunctivitis SiccaItalien
-
C.O.C. Farmaceutici S.r.l.AfsluttetTørre øjne | Tør øjensygdom | Kerato Conjunctivitis SiccaItalien
Kliniske forsøg med Lastacaft ®
-
Starx Research Center, LLCUkendtAllergisk konjunktivitis | RhinoconjunctivitisForenede Stater
-
AllerganAfsluttetKonjunktivitis, AllergiskKorea, Republikken
-
AllerganAfsluttetKonjunktivitis, AllergiskForenede Stater
-
Galderma R&DAfsluttetAtopisk dermatitisFilippinerne, Kina
-
Dong-A ST Co., Ltd.AfsluttetFunktionel dyspepsiKorea, Republikken
-
Chong Kun Dang PharmaceuticalAfsluttet
-
Chung-Ang University Hosptial, Chung-Ang University...UkendtFunktionel dyspepsiKorea, Republikken
-
University of MiamiBSN Medical IncAfsluttet
-
Sanofi Pasteur, a Sanofi CompanyAfsluttetPertussis | Difteri | PolioForenede Stater
-
Amir AzarpazhoohInstitut Straumann AGAfsluttet